[Definitions](index=4&type=section&id=Item%201.%20Definitions) This chapter defines professional terms and company entity abbreviations used in the report, including regulatory bodies, the company and its main subsidiaries, and common abbreviations in the pharmaceutical R&D industry - This chapter primarily explains professional terms and company entity abbreviations used in the report, including regulatory bodies (e.g., CSRC), the company and its main subsidiaries (e.g., Huawei Pharma, Lihua Bio), and common abbreviations in the pharmaceutical R&D industry (e.g., CRO, CMO, MAH)[7](index=7&type=chunk) [Company Profile and Key Financial Indicators](index=4&type=section&id=Item%202.%20Company%20Profile%20and%20Key%20Financial%20Indicators) The company achieved significant performance growth in the reporting period, with substantial increases in revenue, net profit, and operating cash flow, driven by market expansion and improved efficiency [Company Information](index=4&type=section&id=2.1%20Company%20Information) This chapter provides the company's basic business registration information, including Chinese and English names, legal representative, board secretary contact details, and registered and office addresses Company Information | Item | Information | | :--- | :--- | | **Company Chinese Name** | Xinjiang Baihuacun Pharmaceutical Group Co., Ltd. | | **Company Chinese Abbreviation** | Baihua Pharma | | **Stock Code** | 600721 | | **Legal Representative** | Zheng Caihong | | **Registered Address** | No. 3 R&D Office Building, Weiliu West Street 699, East Industrial Park, Wujiaqu City, Xinjiang | | **Office Address** | No. 1 Zhongshan Road South Lane, Tianshan District, Urumqi City, Xinjiang | [Key Accounting Data and Financial Indicators](index=5&type=section&id=2.2%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company achieved significant performance growth, with revenue increasing by 17.40%, net profit attributable to shareholders by 74.32%, and operating cash flow by 774.92% Key Accounting Data (January-June 2024) | Key Accounting Data | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | CNY 196,304,097.42 | CNY 167,213,932.12 | 17.40% | | Net Profit Attributable to Shareholders | CNY 22,660,985.62 | CNY 12,999,556.43 | 74.32% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | CNY 21,138,269.74 | CNY 12,277,137.65 | 72.18% | | Net Cash Flow from Operating Activities | CNY 53,766,073.92 | CNY 6,145,234.85 | 774.92% | | **Asset Status** | **End of Current Period** | **End of Prior Year** | **YoY Change (%)** | | Net Assets Attributable to Shareholders | CNY 732,950,285.39 | CNY 706,615,374.07 | 3.73% | | Total Assets | CNY 1,112,372,470.42 | CNY 1,062,010,154.10 | 4.74% | Key Financial Indicators (January-June 2024) | Key Financial Indicators | Current Period (Jan-Jun) | Prior Period | Change | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (CNY/share) | 0.0594 | 0.0344 | 72.67% | | Weighted Average Return on Net Assets (%) | 3.16% | 1.93% | Increase of 1.23 percentage points | | Weighted Average Return on Net Assets (Excluding Non-recurring Items) (%) | 2.95% | 1.82% | Increase of 1.13 percentage points | - Performance growth was primarily driven by **17.40% revenue increase** from market expansion, **1.71% gross margin growth** in the pharmaceutical sector due to improved R&D efficiency, and a **3.98% reduction in overall expense ratio** from effective cost control[15](index=15&type=chunk) - Total non-recurring gains and losses for the reporting period amounted to **CNY 1,522,715.88**, mainly from fair value changes of financial assets held by non-financial enterprises and government subsidies[16](index=16&type=chunk) [Management Discussion and Analysis](index=7&type=section&id=Item%203.%20Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the company's industry, core competencies, operating performance, and financial position, highlighting key drivers and potential risks [Industry and Main Business Overview for the Reporting Period](index=7&type=section&id=3.1%20Industry%20and%20Main%20Business%20Overview%20for%20the%20Reporting%20Period) The Chinese CRO industry, where the company operates, is poised for rapid growth, with the company providing comprehensive, one-stop outsourced R&D and technology transfer services - The Chinese CRO market size is projected to reach **CNY 307.67 billion** by 2030, growing at a **CAGR of 19.9%**, significantly outpacing the global market[17](index=17&type=chunk) - The company's main business covers the entire new drug R&D process, including early discovery, CMC development, clinical trials, registration and declaration, bioanalytical services, SMO, and MAH services[18](index=18&type=chunk) [Analysis of Core Competencies for the Reporting Period](index=8&type=section&id=3.2%20Analysis%20of%20Core%20Competencies%20for%20the%20Reporting%20Period) The company's core strengths include comprehensive "pharmaceutical research + clinical services + bioanalysis" capabilities, advanced facilities, a highly skilled professional team, extensive R&D experience, and robust quality management - The company provides **one-stop services** from drug discovery to registration and declaration, offering strong business synergy that saves clients R&D costs and time[22](index=22&type=chunk) - The company possesses a **30,000 square meter R&D building** with advanced equipment, where **86.03% of employees hold bachelor's degrees or higher**, and R&D and management personnel account for **95.52%**[23](index=23&type=chunk) - The company has established **five major formulation technology platforms**, obtained **79 patent authorizations**, and cumulatively secured over **400 domestic registration and production approvals** and clinical trial approvals[24](index=24&type=chunk) [Discussion and Analysis of Operating Results](index=9&type=section&id=3.3%20Discussion%20and%20Analysis%20of%20Operating%20Results) In H1 2024, the company achieved CNY 196 million in revenue and CNY 22.66 million in net profit, driven by enhanced core services, cost control, increased R&D investment, and strong order book growth Overall Operating Performance for H1 2024 | Indicator | Amount | YoY Growth | | :--- | :--- | :--- | | Total Operating Revenue | CNY 196 million | 17.40% | | Net Profit Attributable to Shareholders | CNY 22.66 million | - | | Net Profit (Excluding Non-recurring Items) | CNY 21.14 million | 72.18% | | Net Cash Flow from Operating Activities | CNY 53.77 million | 774.92% | - During the reporting period, the company's R&D investment totaled **CNY 20.42 million**, a **41.48% year-on-year increase**, primarily directed towards anti-tumor, ophthalmic, and SGLT2 inhibitor combination drug fields[31](index=31&type=chunk) - The company strengthened business synergy, adding **CNY 210 million** in new pharmaceutical main business contracts during the reporting period, with **CNY 1.115 billion** in outstanding orders as of the end of the period[31](index=31&type=chunk) - During the reporting period, the number of declared project specifications increased by **111% year-on-year**, and approved specifications increased by **26% year-on-year**, with a cumulative total of **6 generic drugs** being the first to be approved or pass consistency evaluation[31](index=31&type=chunk) [Key Operating Results for the Reporting Period](index=11&type=section&id=3.4%20Key%20Operating%20Results%20for%20the%20Reporting%20Period) This section analyzes financial statement changes, asset and liability status, investments, subsidiary performance, and risks, highlighting revenue growth from R&D, improved cash flow, and significant asset shifts [Main Business Analysis](index=11&type=section&id=3.4.1%20Main%20Business%20Analysis) Operating revenue increased by 17.40%, driven by enhanced efficiency in pharmaceutical R&D and clinical research, while operating costs grew at a slower rate, and net cash flow from operations surged due to improved project collections Analysis of Major Financial Statement Item Changes | Item | Current Period (CNY) | Prior Period (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 196,304,097.42 | 167,213,932.12 | 17.40 | | Operating Cost | 102,564,923.99 | 89,000,953.87 | 15.24 | | Net Cash Flow from Operating Activities | 53,766,073.92 | 6,145,234.85 | 774.92 | | Net Cash Flow from Investing Activities | -95,681,306.56 | -76,785,978.98 | -24.61 | | Investment Income | 1,744,495.09 | 947,597.30 | 84.10 | [Analysis of Assets and Liabilities](index=13&type=section&id=3.4.2%20Analysis%20of%20Assets%20and%20Liabilities) Total assets reached CNY 1.112 billion, with significant shifts including a decrease in cash due to bank wealth product purchases, a substantial increase in accounts receivable from R&D projects, and growth in development expenditures for MAH projects Changes in Major Asset and Liability Items | Item Name | Current Period End (CNY) | Prior Year End (CNY) | Change (%) | Primary Reason | | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 161,732,145.76 | 202,070,585.90 | -19.96 | Purchase of bank wealth management products | | Financial Assets Held for Trading | 75,280,000.00 | 0.00 | 100.00 | Increase due to purchase of bank wealth management products | | Accounts Receivable | 33,708,627.74 | 16,448,667.57 | 104.93 | Increase in receivables from pharmaceutical R&D projects | | Prepayments | 8,908,166.51 | 5,031,328.63 | 77.05 | Increase in prepayments for clinical trial projects | | Development Expenditures | 16,958,969.16 | 10,487,849.93 | 61.70 | Increase in capitalized expenditures for MAH projects | [Analysis of Major Holding and Associate Companies](index=16&type=section&id=3.4.3%20Analysis%20of%20Major%20Holding%20and%20Associate%20Companies) Nanjing Huawei Pharma and Jiangsu Lihua Bio reported strong net profit growth due to increased sales and improved margins, while Nanjing Huanglong Bio's loss widened due to increased R&D investment in MAH projects Operating Performance of Major Subsidiaries (January-June 2024) | Subsidiary | Current Period Operating Revenue (CNY Million) | Current Period Net Profit (CNY Million) | Net Profit Change Rate (%) | Explanation of Change | | :--- | :--- | :--- | :--- | :--- | | Nanjing Huawei Pharma | 153.19 | 19.49 | 63.48% | Increased sales, gross margin growth | | Jiangsu Lihua Bio | 76.00 | 3.62 | 90.21% | Increased sales, reduced expense ratio | | Nanjing Huanglong Bio | 2.14 | -3.17 | -43.58% | Increased R&D investment in MAH projects | [Potential Risks](index=16&type=section&id=3.4.4%20Potential%20Risks) The company faces significant risks from intensifying market competition, uncertain industry policy changes, long R&D project cycles, rising R&D costs, and potential loss of professional technical talent - The company faces multiple risks including market competition, industry policy changes, long-cycle contract execution, rising R&D costs, and talent attrition[43](index=43&type=chunk)[44](index=44&type=chunk)[45](index=45&type=chunk)[46](index=46&type=chunk)[47](index=47&type=chunk) [Corporate Governance](index=17&type=section&id=Item%204.%20Corporate%20Governance) The company held its annual and extraordinary general meetings, appointed a new board secretary, and continues to implement its 2021 stock option incentive plan and 2016 employee stock ownership plan [Corporate Governance Status](index=17&type=section&id=4.1%20Corporate%20Governance%20Status) During the reporting period, the company held shareholder meetings, appointed a new board secretary, and continued to execute its stock option incentive and employee stock ownership plans - During the reporting period, the company appointed **Ms. Zhao Qinqin** as Board Secretary, with CFO Cai Ziyun no longer concurrently holding the position[50](index=50&type=chunk) - The company's board of directors resolved that there is **no profit distribution plan or capital reserve capitalization plan** for the current reporting period[51](index=51&type=chunk) - The company's **2021 stock option incentive plan** continues to progress, with some options meeting exercise conditions, and the **2016 employee stock ownership plan** remains in effect, with **1,952,200 shares** remaining at period-end[52](index=52&type=chunk)[54](index=54&type=chunk) [Environmental and Social Responsibility](index=19&type=section&id=Item%205.%20Environmental%20and%20Social%20Responsibility) The company is not a key polluter and adheres to strict environmental protection policies, managing wastewater, exhaust gas, solid waste, and noise effectively, while promoting low-carbon practices [Environmental Information](index=19&type=section&id=5.1%20Environmental%20Information) The company is not a key polluting entity and strictly implements environmental protection measures for wastewater, exhaust gas, solid waste, and noise, promoting low-carbon operations - The company is **not classified as a key polluting entity** and has established multiple environmental management systems, including the 'Safety and Environmental Work Management Measures'[54](index=54&type=chunk)[56](index=56&type=chunk) - The company professionally treats experimental wastewater and exhaust gas to ensure compliance with discharge standards, and hazardous waste is safely disposed of by qualified professional institutions[54](index=54&type=chunk)[55](index=55&type=chunk) - The company implements green and low-carbon principles by advocating for low-carbon office practices and green travel to reduce carbon emissions[57](index=57&type=chunk) [Significant Matters](index=22&type=section&id=Item%206.%20Significant%20Matters) This section covers the fulfillment of commitments, penalties for alleged violations, and significant related-party transactions, highlighting both compliance and areas requiring rectification [Fulfillment of Commitments](index=22&type=section&id=6.1%20Fulfillment%20of%20Commitments) The company's controlling shareholder and actual controller have strictly fulfilled their commitments regarding avoiding horizontal competition and reducing related-party transactions, though one party from a major asset restructuring has not yet fulfilled their commitment - The company's controlling shareholder, Hualing Industrial & Trade, and the new actual controller, Hualing Holdings, have both committed to avoiding horizontal competition and regulating related-party transactions, and have strictly fulfilled these commitments during the reporting period[58](index=58&type=chunk)[59](index=59&type=chunk) - Mr. Zhang Xiaoqing, a counterparty in the 2016 major asset restructuring, failed to timely fulfill his 'Commitment Letter on Avoiding Horizontal Competition,' and the company has urged him to fulfill his commitment[59](index=59&type=chunk)[61](index=61&type=chunk) [Alleged Violations, Penalties and Rectification](index=27&type=section&id=6.2%20Alleged%20Violations%2C%20Penalties%20and%20Rectification) The company's controlling shareholder and actual controller received criticism and warning letters in June 2024 for information disclosure issues, prompting the company to enhance compliance and disclosure quality - The company's controlling shareholder and actual controller received a **circular criticism from the Shanghai Stock Exchange** and a **warning letter from the Xinjiang CSRC Bureau** in June 2024[66](index=66&type=chunk) - The company pledges to strengthen its study of laws and regulations, improve information disclosure quality, and urge shareholders to standardize their conduct and fulfill their obligations[66](index=66&type=chunk) [Significant Related Party Transactions](index=27&type=section&id=6.3%20Significant%20Related%20Party%20Transactions) The company's routine related-party transactions primarily involve its associate, Kangyuan Huawei Pharma, with subsidiaries Huawei Pharma and Lihua Bio providing R&D and clinical services, generating CNY 0.42 million and CNY 2.87 million in revenue respectively - Subsidiary Huawei Pharma's pharmaceutical R&D service transactions with related party Kangyuan Huawei generated **CNY 0.42 million** in revenue for the current period[67](index=67&type=chunk) - Subsidiary Lihua Bio provided clinical services to related party Kangyuan Huawei, signing contracts worth **CNY 9.3 million** and realizing **CNY 2.87 million** in revenue for the current period[67](index=67&type=chunk) [Share Changes and Shareholder Information](index=30&type=section&id=Item%207.%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital due to stock option exercises, provides an overview of its shareholder structure, and explains the recent change in actual control [Share Capital Changes](index=30&type=section&id=7.1%20Share%20Capital%20Changes) The company's total share capital increased by 300,625 shares to 381,993,270 shares due to the exercise of stock options under the 2021 incentive plan, all of which are unrestricted tradable shares - As of June 30, 2024, due to the exercise of stock options under the incentive plan, the company's total share capital increased by **300,625 shares** to **381,993,270 shares**[70](index=70&type=chunk)[71](index=71&type=chunk) [Shareholder Information](index=31&type=section&id=7.2%20Shareholder%20Information) As of the reporting period end, the company had 36,816 common shareholders, with Xinjiang Hualing Industrial & Trade (Group) Co., Ltd. as the largest shareholder, holding 20.82% of shares, all of which are pledged Top Ten Shareholders' Holdings (As of June 30, 2024) | Shareholder Name | Number of Shares Held (shares) | Proportion (%) | Share Status | | :--- | :--- | :--- | :--- | | Xinjiang Hualing Industrial & Trade (Group) Co., Ltd. | 79,525,087 | 20.82 | Pledged | | Xinjiang Xinnong Modern Investment Development Co., Ltd. | 16,873,556 | 4.42 | - | | Li Jiancheng | 15,000,000 | 3.93 | - | | Zhang Xiaoqing | 9,876,775 | 2.59 | - | | Zhang Desheng | 8,149,601 | 2.13 | - | - The largest shareholder, Xinjiang Hualing Industrial & Trade (Group) Co., Ltd., has **pledged all 79,525,087 shares** it holds[73](index=73&type=chunk) [Changes in Controlling Shareholder or Actual Controller](index=33&type=section&id=7.3%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) On February 8, 2024, the company's actual controller changed to Mi Zaiqi, Mi Enhua, and Yang Xiaoling, following Hualing Holdings' capital increase in the controlling shareholder, Hualing Industrial & Trade - Due to a capital increase at the controlling shareholder level, the company's actual controllers changed from **Mi Enhua and Yang Xiaoling (couple)** to **Mi Zaiqi, Mi Enhua, and Yang Xiaoling**[78](index=78&type=chunk) [Financial Report](index=34&type=section&id=Item%2010.%20Financial%20Report) This section presents the company's consolidated and parent company financial statements for H1 2024, including balance sheets, income statements, cash flow statements, and statements of changes in equity, showing overall growth and improved cash flow [Financial Statements](index=34&type=section&id=10.1%20Financial%20Statements) This chapter provides the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for H1 2024, indicating growth in assets, net assets, and net profit, with significantly improved operating cash flow - The consolidated balance sheet shows that as of June 30, 2024, the company's total assets were **CNY 1.112 billion**, with owners' equity attributable to the parent company at **CNY 733 million**[80](index=80&type=chunk)[81](index=81&type=chunk) - The consolidated income statement indicates that total operating revenue for H1 2024 was **CNY 196 million**, with net profit attributable to parent company shareholders at **CNY 22.66 million**[84](index=84&type=chunk)[85](index=85&type=chunk) - The consolidated cash flow statement shows that net cash flow from operating activities for H1 2024 was **CNY 53.77 million**, a significant increase from **CNY 6.15 million** in the prior year period[88](index=88&type=chunk) [Company Overview and Basis of Financial Statement Preparation](index=45&type=section&id=10.2%20Company%20Overview%20and%20Basis%20of%20Financial%20Statement%20Preparation) This chapter outlines the company's historical development, registration details, and business scope, clarifying that financial statements are prepared under the going concern assumption in accordance with Accounting Standards for Business Enterprises - The company was listed on the Shanghai Stock Exchange in **June 1996**, and after multiple share capital changes and business restructurings, it was renamed 'Xinjiang Baihuacun Pharmaceutical Group Co., Ltd.' in **2022**, focusing on pharmaceutical R&D business[94](index=94&type=chunk)[99](index=99&type=chunk) - Financial statements are prepared on a **going concern basis**, with the accounting year being the calendar year and the functional currency being **RMB**[103](index=103&type=chunk)[104](index=104&type=chunk)[106](index=106&type=chunk) [Significant Accounting Policies and Estimates](index=48&type=section&id=10.3%20Significant%20Accounting%20Policies%20and%20Estimates) This chapter details the company's key accounting policies and estimates, covering business combinations, consolidated financial statements, financial instruments, inventories, long-term equity investments, fixed assets, intangible assets, revenue recognition, government grants, and leases - Revenue from pharmaceutical R&D, consistency evaluation, and clinical trial services is primarily recognized using the **percentage-of-completion method**[168](index=168&type=chunk) - Investment properties are subsequently measured using the **fair value model**[145](index=145&type=chunk)[146](index=146&type=chunk) - R&D expenditures are distinguished between research and development phases, with development phase expenditures meeting capitalization criteria recognized as **intangible assets**[155](index=155&type=chunk) [Notes to Consolidated Financial Statement Items](index=81&type=section&id=10.4%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This chapter provides detailed notes on key consolidated financial statement items, including significant balances for accounts receivable, contract assets, inventories, and goodwill, along with their respective impairment provisions and investments in associates - Accounts receivable had an ending book balance of **CNY 47.17 million**, with a bad debt provision of **CNY 13.47 million**; contract assets had an ending book balance of **CNY 242 million**, with a bad debt provision of **CNY 65.32 million**[192](index=192&type=chunk)[198](index=198&type=chunk) - Inventory had an ending book value of **CNY 127 million**, with **CNY 121 million** attributed to R&D projects, and an inventory impairment provision of **CNY 92.18 million** already made[219](index=219&type=chunk)[220](index=220&type=chunk) - Goodwill had an original book value of **CNY 1.704 billion**, primarily from the acquisition of Nanjing Huawei Pharma, with an impairment provision of **CNY 1.693 billion** already made, resulting in an ending book value of **CNY 11.49 million**[237](index=237&type=chunk)[238](index=238&type=chunk) - Long-term equity investments had an ending balance of **CNY 59.79 million**, representing the investment in associate company Kangyuan Huawei Pharmaceutical Co., Ltd[225](index=225&type=chunk)

新疆百花村医药集团股份有限公司 2024 年第二次临时股东大会议程 新疆百花村医药集团股份有限公司 新疆百花村医药集团股份有限公司 2024 年第二次临时股东大会会议资料 2024 年 8 月 26 日 新疆百花村医药集团股份有限公司 目 录 | 新疆百花村医药集团股份有限公司 2024 年第二次临时股东大会议程 3 | | --- | | 议案一：公司关于提名公司第九届董事会董事候选人的议案 4 | | 议案二：公司关于提名公司第九届监事会非职工监事候选人的议案 7 | | 议案三：公司关于提名公司第九届董事会独立董事候选人的议案 8 | 2 / 10 （2024 年 8 月 26 日） 新疆百花村医药集团股份有限公司 | 序 号 | 事 | 项 | | --- | --- | --- | | 宣布公司 | 年第二次临时股东大会正式开始 2024 | | | 一 | 介绍会议出席情况 | | | 二 | 推选计票人及监票人 | | | 三 | 宣读并审议议案 | | | | 非累积投票议案 | | | 1 | 《公司关于提名公司第九届董事会董事候选人的议案》 | | | 2 | 《公司关于提名公司第九届监事 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2024-056 新疆百花村医药集团股份有限公司 关于对 2021 年股票期权激励计划股票期权 部分注销完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股权激励管理办法》《公司 2021 年股票期权激励计划（草 案）》相关规定，公司对 2021 年股票期权激励计划首次授予和预留授予激励对 象未达到行权条件、经考核行权系数确定为非 A 级的员工部分股票期权，合计 2,718,205 份股票期权进行注销，注销工作完成后，公司 2021 年股票期权激励计 划首次授予和预留授予的激励对象由 177 名调整为 150 名，持有已获授尚未行权 的股票期权数量从 5,251,450 份调整为 2,533,245 份。具体详见同日在上海证券交 易所网站（www.sse.com.cn）、上海证券报和证券日报上披露的《公司关于对 2021 年股票期权激励计划股票期权部分予以注销的公告》（公告编号：2024-048）。 公司向中国证券登记 ...

公司董事会对韩丽娟女士在任职期间所做出的工作表示衷心的感谢！ 特此公告。 新疆百花村医药集团股份有限公司董事会 2024 年 8 月 9 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 新疆百花村医药集团股份有限公司（以下简称"公司"）董事会近日收到公 司证券事务代表韩丽娟女士提交的辞职报告。韩丽娟女士因个人工作变动原因辞 去公司证券事务代表职务，辞职后将不再担任公司任何职务。根据《上海证券交 易所股票上市规则》《公司章程》等相关规定，韩丽娟女士的辞职报告自送达董 事会之日起生效。 韩丽娟女士的辞职不会影响公司相关工作的正常开展，公司董事会将根据相 关规定，履行程序聘任证券事务代表。 新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2024-055 新疆百花村医药集团股份有限公司 关于证券事务代表辞职的公告 ...

1、截至目前,除已披露事项外,新疆华凌工贸(集团)有限公司不存在涉 及新疆百花村医药集团股份有限公司的应披露而未披露的重大信息,包括但不限 于重大资产重组、股份发行、重大交易类事项、业务重组、股份回购、股权激励、 破产重整、重大业务合作、引进战略投资者等重大事项。 2、在新疆百花村医药集团股份有限公司本次股票交易异常波动期间,新疆 华凌工贸(集团)有限公司不存在买卖公司股票的情况。 特此回复。 新疆 百 1 B b g � 关于新疆百花村医药集团股份有限公司 股票交易异常波动询证函的回复 新疆自花村医药集团股份有限公司: 《关于新疆百花村医药集团股份有限公司股票交易异常波动的询证函》已收 悉,经核查,现回复如下: ...

关于新疆百花村医药集团股份有限公司 股票交易异常波动询证函的回复 米恩华 米在齐 2024 年 8 月 5 日 杨小玲 1、截至目前,除已披露事项外,不存在涉及新疆百花村医药集团股份有限 公司的应披露而未披露的重大信息,包括但不限于重大资产重组、股份发行、重 大交易类事项、业务重组、股份回购、股权激励、破产重整、重大业务合作、引 进战略投资者等重大事项。 2、在新疆百花村医药集团股份有限公司本次股票交易异常波动期间,不存 在买卖公司股票的情况。 特此回复。 新疆百花村医药集团股份有限公司: 《关于新疆百花村医药集团股份有限公司股票交易异常波动的询证函》已收 悉,经核查,现回复如下: ...

新疆百花村医药集团股份有限公司 二、公司关注并核实的相关情况 证券代码：600721 证券简称：百花医药 公告编号：2024-054 新疆百花村医药集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 新疆百花村医药集团股份有限公司（以下简称"公司"）股票在连续三 个交易日内日收盘价格涨幅偏离值累计达到 20%。根据《上海证券交易所股票上 市规则》（以下简称"上市规则"）的有关规定，属于股票交易异常波动。 经公司自查并向控股股东新疆华凌工贸（集团）有限公司（以下简称"华 凌集团"）及实控人核实，除公司已披露公告之外，不存在应披露而未披露的重 大信息。 公司生产经营环境未发生重大变化，生产经营情况正常。 一、股票交易异常波动的具体情况 公司股票于 2024 年 8 月 1 日、2024 年 8 月 2 日、2024 年 8 月 5 日连续三个 交易日内日收盘价格涨幅偏离值累计达到 20%，根据《上市规则》的有关规定， 属于股票交易异常波动。 （一）生产经营情况 经公司自查，截至目 ...

独立董事候选人声明与承诺 本人谷莉,已充分了解并同意由提名人新疆百花村医药集团 股份有限公司董事会提名为新疆百花村医药集团股份有限公司 第九届董事会独立董事候选人。本人公开声明,本人具备独立董 事任职资格,保证不存在任何影响本人担任新疆百花村医药集团 股份有限公司独立董事独立性的关系,具体声明并承诺如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、部门规章及其他规范性文件,具有5年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 本人已经参加培训并取得证券交易所认可的相关培训证明 材料。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求: (一)《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的 规定(如适用); (三)中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定; (四)中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退(离)休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定(如适用); ( ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2024-051 新疆百花村医药集团股份有限公司 关于董事会、监事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 新疆百花村医药集团股份有限公司（以下简称"公司"）第八届董事会任期 至 2024 年 9 月 16 日届满，根据《公司法》《公司章程》等相关规定，公司于 2024 年 7 月 31 日召开的第八届董事会第二十七次会议审议通过了《公司关于提 名公司第九届董事会董事候选人的议案》《公司关于提名公司第九届董事会独立 董事候选人的议案》，同日召开第八届监事会第十八次会议审议通过了《公司关 于提名公司第九届监事会非职工监事候选人的议案》，上述事项尚需提交公司股 东大会审议。现将本次董事会、监事会换届选举情况说明如下： 一、董事会换届选举情况 公司第九届董事会将由 11 名董事组成，其中独立董事 4 名，董事任期自公 司股东大会选举通过之日起三年。根据公司董事会提名委员会对第九届董事会候 选人资格的审查结果，公司股东、董事会 ...

新疆百花村医药集团股份有限公司 证券代码：600721 证券简称：百花医药 公告编号：2024-048 2、2021 年 6 月 25 日，公司召开第七届监事会第二十次会议，会议审议通 过了《关于公司〈激励计划〉及其摘要的议案》《关于公司〈2021 年股票期权 激励计划实施考核管理办法〉的议案》及《关于〈公司 2021 年股票期权激励计 划激励对象名单〉的议案》。 1 / 5 新疆百花村医药集团股份有限公司 3、2021 年 6 月 26 日至 2021 年 7 月 5 日，公司在内部公告栏对激励对象名 单予以公示。在公示的时限内，公司监事会未接到与本激励计划激励对象有关的 任何异议。2021 年 7 月 7 日，公司对外披露了《监事会关于公司 2021 年股票期 权激励计划激励对象名单的核查意见》。 4、2021 年 7 月 15 日，公司召开 2021 年第四次临时股东大会，审议通过了 《关于公司〈激励计划〉及其摘要的议案》《关于公司〈2021 年股票期权激励 计划实施考核管理办法〉的议案》《关于提请股东大会授权董事会办理公司 2021 年股票期权激励计划有关事项的议案》；公司董事会被授权确定股票期权授予 ...